March 4, 2020 / 12:42 PM / a month ago

BRIEF-Vir And Alnylam Expand Collaboration To Advance RNAi Therapeutics For Treatment Of Coronavirus Infection, Including Covid-19

March 4 (Reuters) - Alnylam Pharmaceuticals Inc:

* VIR AND ALNYLAM EXPAND COLLABORATION TO ADVANCE RNAI THERAPEUTICS FOR THE TREATMENT OF CORONAVIRUS INFECTION, INCLUDING COVID-19

* ALNYLAM PHARMA - RECENT ALNYLAM ADVANCES IN LUNG DELIVERY TECHNOLOGY SUGGEST POSSIBLE UTILITY OF SIRNAS IN TARGETING SARS-COV-2

* ALNYLAM PHARMACEUTICALS - VIR TO LEAD DEVELOPMENT OF POTENTIAL CORONAVIRUS RNAI THERAPEUTIC CANDIDATES, WITH CO RETAINING OPTION FOR 50-50 PARTICIPATION

* ALNYLAM PHARMA - FOCUS ON DEVELOPMENT OF SIRNAS THAT ALNYLAM IDENTIFIED THAT TARGET HIGHLY CONSERVED REGIONS OF CORONAVIRUS RNAS

* ALNYLAM PHARM - MAY ELECT TO EARN DEVELOPMENT, COMMERCIALIZATION MILESTONES & ROYALTIES ON NET SALES OF PRODUCTS FOR CORONAVIRUS PROGRAM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below